However, despite this activation, treatment with sunitinib led to the accumulation of p62/SQSTM1 protein in bladder cancer cells, implying impaired lysosomal degradation or incomplete autophagolysosome formation [154]. The gene discussed is SQSTM1; the disease is urinary bladder carcinoma.